Astellas Pharma Inc.  _ Annual Report 2014 156 (ii) Reconciliation of profit or loss and comprehensive income for the year ended 31 March 2013 (Millions of yen) Japanese GAAP Japanese  GAAP Presentation Recognition and  measurement IFRS Note IFRS Net sales ¥1,005,612 ¥ (2,682) ¥(21,031) ¥ 981,899 A Sales Cost of sales (324,127) (3,077) 18,493 (308,711) B Cost of sales Gross profit 681,485 (5,760) (2,538) 673,187 Gross profit Selling, general and administrative expenses (527,618) 197,838 10,837 (318,943) C Selling, general and administrative expenses — (165,629) 6,534 (159,094) D Research and development  expenses — (25,514) (2,752) (28,266) E Amortisation of intangible  assets — 1,137 — 1,137 F Share of profits of associates and joint ventures — 2,861 1 2,862 G Other income — (39,651) (9,640) (49,291) H Other expense Operating income 153,867 (34,716) 2,442 121,593 Operating profit Non-operating income 4,053 (4,053) — — Non-operating expenses (764) 764 — — Special gains 5,811 (5,811) — — Special losses (38,294) 38,294 — — — 7,339 — 7,339 I Finance income — (1,816) — (1,816) J Finance expense Income before income taxes  and minority interests 124,673 — 2,442 127,115 Profit before tax Income taxes (41,822) — 7,171 (34,651) K Income tax expense Net income 82,851 — 9,613 92,464 Profit for the year Other comprehensive income Other comprehensive income — — (5,049) (5,049) L Remeasurements of defined benefit plans Foreign currency translation  adjustments 66,241 — 1,418 67,659 M Foreign currency translation  adjustments Unrealised holding gains on securities 3,709 — (435) 3,273 N Fair value movements on available-for-sale financial  assets Other comprehensive income, net of tax 69,950 — (4,066) 65,883 Other comprehensive income, net of tax Total comprehensive income ¥ 152,801 ¥ — ¥ 5,547 ¥ 158,347 Total comprehensive income